2020.10.28
I-Mab Announces Upcoming Participation at November Conferences
I-Mab today announced its participation in the following conferences in November. Details of the conferences and management presentation are as follows.
2020.10.27
I-Mab to Present Preclinical Data of TJ210 at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Oral presentation will highlight the potent anti-tumor effects demonstrated by TJ210, a novel antibody that blocks C5aR by binding to a unique epitope.
2020.10.15
I-Mab to Present Phase 1 Data of Lemzoparlimab at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Poster presentation highlights data from the U.S. phase 1 trial of lemzoparlimab, a highly differentiated anti-CD47 monoclonal antibody, for treatment of relapsed or refractory malignancy.
2020.09.30
I-Mab Receives China CDE Approval to Initiate Phase 3 Clinical Trial of Eftansomatropin in Pediatric Patients with Growth Hormone Deficiency
I-Mab today announced that the China Center for Drug Evaluation has approved the pivotal trial application for eftansomatropin as a weekly treatment for growth hormone deficiency in pediatric patients.
2020.09.21
I-Mab Announces China NMPA Clearance for Phase 1 Clinical Trial of Lemzoparlimab in Relapsed or Refractory Advanced Lymphoma
I-Mab today announced that the Center for Drug Evaluation of the China National Medical Products Administration has cleared the Investigational New Drug application for lemzoparlimab to initiate a phase 1 clinical trial in patients with relapsed or refractory advanced lymphoma as part of an ongoing ...
2020.09.17
MorphoSys and I-Mab Announce FDA Clearance of IND Application for MOR210/TJ210 in Patients with Advanced Cancer
MorphoSys and I-Mab today jointly announced that the U.S. FDA has cleared the IND application for MOR210/TJ210 for the treatment of relapsed or refractory advanced solid tumors. The phase 1 clinical trial, designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of MOR210...
2020.09.08
I-Mab Announces Upcoming Participation at September Conferences
I-Mab today announced its participation in the following conferences in September, including Cantor Fitzgerald Virtual Global Healthcare Conference 2020, Jefferies Virtual Asia Forum, ICBCI Virtual ADR New Economy Conference, 2020 Huatai USA Autumn Virtual China Conference, and Morgan Stanley Virtua...
2020.09.04
I-Mab Announces $418 Million Private Placement with Hillhouse Capital-Led Consortium
I-Mab today announced that it has entered into definitive subscription agreements with a consortium of institutional investors to raise approximately US$418 million through a private placement.
2020.09.04
AbbVie and I-Mab Enter Into Global Strategic Partnership for Differentiated Immuno-oncology Therapy
AbbVie and I-Mab have signed a broad, global collaboration agreement for the development and commercialization of lemzoparlimab (also known as TJC4), an innovative anti-CD47 monoclonal antibody internally discovered and developed by I-Mab for the treatment of multiple cancers. In addition, the two p...
2020.08.31
I-Mab Reports Financial Results for the Six Months Ended June 30 and Provides Corporate Update
I-Mab today announced financial results for the six months ended June 30, 2020 and provided an overview of recent highlights and upcoming milestones.